127 related articles for article (PubMed ID: 18042935)
21. [Ductal carcinoma in situ of the breast].
Barth A; Köchli OR; Brenner RJ; Giuliano E; Castiglione M
Schweiz Med Wochenschr; 1995 Jan; 125(4):103-12. PubMed ID: 7878398
[TBL] [Abstract][Full Text] [Related]
22. [Receptor (ER, PgR) levels as prognostic factors in the endocrine therapy of pre- and post-menopausal patients with stage III infiltrative ductal and lobular cancer of the breast].
Calzada L; Salazar EL; Pedron Nuevo N
Ginecol Obstet Mex; 1996 Mar; 64():135-9. PubMed ID: 8729191
[TBL] [Abstract][Full Text] [Related]
23. Unopposed estrogen therapy and the risk of invasive breast cancer.
Chen WY; Manson JE; Hankinson SE; Rosner B; Holmes MD; Willett WC; Colditz GA
Arch Intern Med; 2006 May; 166(9):1027-32. PubMed ID: 16682578
[TBL] [Abstract][Full Text] [Related]
24. The effect of mammographic screening and hormone replacement therapy use on breast cancer incidence in England and Wales.
Waller M; Moss S; Watson J; Møller H
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2257-61. PubMed ID: 18006913
[TBL] [Abstract][Full Text] [Related]
25. Genetic and environmental predictors, endogenous hormones and growth factors, and risk of estrogen receptor-positive breast cancer in Japanese women.
Yoshimoto N; Nishiyama T; Toyama T; Takahashi S; Shiraki N; Sugiura H; Endo Y; Iwasa M; Fujii Y; Yamashita H
Cancer Sci; 2011 Nov; 102(11):2065-72. PubMed ID: 21790896
[TBL] [Abstract][Full Text] [Related]
26. Trends in breast cancer incidence and mortality in the United States: implications for prevention.
Toriola AT; Colditz GA
Breast Cancer Res Treat; 2013 Apr; 138(3):665-73. PubMed ID: 23546552
[TBL] [Abstract][Full Text] [Related]
27. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.
Kerlikowske K; Miglioretti DL; Ballard-Barbash R; Weaver DL; Buist DS; Barlow WE; Cutter G; Geller BM; Yankaskas B; Taplin SH; Carney PA
J Clin Oncol; 2003 Dec; 21(23):4314-21. PubMed ID: 14645420
[TBL] [Abstract][Full Text] [Related]
28. A study on time trends in incidence of breast cancer - Indian scenario.
Murthy NS; Agarwal UK; Chaudhry K; Saxena S
Eur J Cancer Care (Engl); 2007 Mar; 16(2):185-6. PubMed ID: 17371429
[No Abstract] [Full Text] [Related]
29. The impact of menopausal hormone therapy on the incidence of different breast cancer types--data from the Cancer Registry Hamburg 1991-2006.
Hentschel S; Heinz J; Schmid-Höpfner S; Obi N; Vettorazzi E; Chang-Claude J; Flesch-Janys D
Cancer Epidemiol; 2010 Oct; 34(5):639-43. PubMed ID: 20705533
[TBL] [Abstract][Full Text] [Related]
30. Screening caused rising incidence rates of ductal carcinoma in situ of the breast.
van Steenbergen LN; Voogd AC; Roukema JA; Louwman WJ; Duijm LE; Coebergh JW; van de Poll-Franse LV
Breast Cancer Res Treat; 2009 May; 115(1):181-3. PubMed ID: 18516674
[TBL] [Abstract][Full Text] [Related]
31. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
32. Assessing the effectiveness of a mammography screening service.
Clayforth C; Fritschi L; McEvoy S; Byrne MJ; Wylie E; Threlfall T; Sterrett G; Harvey JM; Jamrozik K
ANZ J Surg; 2005 Aug; 75(8):631-6. PubMed ID: 16076321
[TBL] [Abstract][Full Text] [Related]
33. Hormone replacement therapy and the increase in the incidence of invasive lobular cancer.
Ravdin PM
Breast Dis; 2008-2009; 30():3-8. PubMed ID: 19850989
[TBL] [Abstract][Full Text] [Related]
34. Marked regression of a nonpalpable breast cancer after cessation of hormone replacement therapy.
Harvey SC; DiPiro PJ; Meyer JE
AJR Am J Roentgenol; 1996 Aug; 167(2):394-5. PubMed ID: 8686614
[No Abstract] [Full Text] [Related]
35. Influence of estrogen plus testosterone supplementation on breast cancer.
Ness RB; Albano JD; McTiernan A; Cauley JA
Arch Intern Med; 2009 Jan; 169(1):41-6. PubMed ID: 19139322
[TBL] [Abstract][Full Text] [Related]
36. [Positive sentinel node risk in relation to oestrogen receptors in breast cancer in premenopausal and postmenopausal women].
Bajén MT; Benítez AM; Domènech A; Ricart Y; Mora J; Notta P; Ramal D; Urruticoechea A; Soler T; Martín-Comin J
Rev Esp Med Nucl; 2010; 29(6):289-92. PubMed ID: 20828880
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer incidence and menopausal hormone therapy in Norway from 2004 to 2009: a register-based cohort study.
Suhrke P; Zahl PH
Cancer Med; 2015 Aug; 4(8):1303-8. PubMed ID: 25991514
[TBL] [Abstract][Full Text] [Related]
38. [Metachronous tumors of the breast. Mammographic findings].
Tella S; Occhiato R; Speziale AM; Poggi R; Grasso F; Frasca F; Passariello R
Radiol Med; 1994 Mar; 87(3):245-9. PubMed ID: 8146360
[TBL] [Abstract][Full Text] [Related]
39. Case records of the Massachusetts General Hospital. Case 24-2005. A 58-year-old woman with early-stage estrogen-receptor-positive breast cancer.
Ryan PD; Kopans DB; Sgroi DC
N Engl J Med; 2005 Aug; 353(6):617-22. PubMed ID: 16093471
[No Abstract] [Full Text] [Related]
40. Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland.
Verkooijen HM; Fioretta G; Vlastos G; Morabia A; Schubert H; Sappino AP; Pelte MF; Schäfer P; Kurtz J; Bouchardy C
Int J Cancer; 2003 May; 104(6):778-81. PubMed ID: 12640687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
